Article Details
Retrieved on: 2024-04-30 17:23:56
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses HanAll Biopharma's Q1 2024 financial results, highlighting a significant revenue increase and developments in immunology-related R&D programs for various autoimmune diseases, aligning with the listed tags like 'Autoimmunity' and 'Immunoglobulin G'. The company operates globally, including Indonesia.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here